



Verastem Oncology to Present at Jefferies Healthcare Conference

May 27, 2026 at 7:30 AM EDT

BOSTON--(BUSINESS WIRE)--May 27, 2026-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 8:10 am ET in New York.

A live webcast of the fireside chat can be accessed under "Events & Presentations" on the Company's website at www.verastem.com. A replay of the webcasts will be archived on the website for approximately 90 days following the presentation.

About Verastem Oncology

Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets [AV/MAPKI@ FAKZYNJA@ CO-PACK](#) in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including [RAF/MEK inhibition](#), [FAK inhibition](#), and [KRAS G12D inhibition](#). For more information, please visit www.verastem.com and follow us on [LinkedIn](#).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20260527590882/en/>

For Investor and Media Inquiries:

Julissa Viana
Senior Vice President, Corporate Communications,
Investor Relations & Patient Advocacy
investors@verastem.com or
media@verastem.com

Source: Verastem Oncology